@article{SeifEinseleLoeffler2019,
  author    = {Seif, Michelle and Einsele, Hermann and L{\"o}ffler, J{\"u}rgen},
  title     = {CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases},
  series = {Frontiers in Immunology},
  volume    = {10},
  journal   = {Frontiers in Immunology},
  number    = {2711},
  issn      = {1664-3224},
  doi       = {10.3389/fimmu.2019.02711},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-195596},
  year      = {2019},
  abstract  = {Infectious diseases are still a significant cause of morbidity and mortality worldwide. Despite the progress in drug development, the occurrence of microbial resistance is still a significant concern. Alternative therapeutic strategies are required for non-responding or relapsing patients. Chimeric antigen receptor (CAR) T cells has revolutionized cancer immunotherapy, providing a potential therapeutic option for patients who are unresponsive to standard treatments. Recently two CAR T cell therapies, Yescarta® (Kite Pharma/Gilead) and Kymriah® (Novartis) were approved by the FDA for the treatments of certain types of non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia, respectively. The success of adoptive CAR T cell therapy for cancer has inspired researchers to develop CARs for the treatment of infectious diseases. Here, we review the main achievements in CAR T cell therapy targeting viral infections, including Human Immunodeficiency Virus, Hepatitis C Virus, Hepatitis B Virus, Human Cytomegalovirus, and opportunistic fungal infections such as invasive aspergillosis.},
  language  = {en}
}
@article{GrafMondorfKnopetal.2019,
  author    = {Graf, Christiana and Mondorf, Antonia and Knop, Viola and Peiffer, Kai-Henrik and Dietz, Julia and Friess, Julia and Wedemeyer, Heiner and Buggisch, Peter and Mauss, Stefan and Berg, Thomas and Rausch, Michael and Sprinzl, Martin and Klinker, Hartwig and Hinrichsen, Holger and Bronowicki, Jean-Pierre and Haag, Sebastian and H{\"u}ppe, Dietrich and Lutz, Thomas and Poynard, Thierry and Zeuzem, Stefan and Friedrich-Rust, Mireen and Sarrazin, Christoph and Vermehren, Johannes},
  title     = {Evaluation of point shear wave elastography using acoustic radiation force impulse imaging for longitudinal fibrosis assessment in patients with HBeAg-Negative HBV infection},
  series = {Journal of Clinical Medicine},
  volume    = {8},
  journal   = {Journal of Clinical Medicine},
  number    = {12},
  issn      = {2077-0383},
  doi       = {10.3390/jcm8122101},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-193916},
  year      = {2019},
  abstract  = {Background: Accurate assessment of hepatic fibrosis in patients with chronic HBeAg-negative Hepatitis B is of crucial importance not only to predict the long-term clinical course, but also to evaluate antiviral therapy indication. The aim of this study was to prospectively assess the utility of point shear wave elastography (pSWE) for longitudinal non-invasive fibrosis assessment in a large cohort of untreated patients with chronic HBeAg-negative hepatitis B virus (HBV) infection. Methods: 407 consecutive patients with HBeAg-negative HBV infection who underwent pSWE, transient elastography (TE) as well as laboratory fibrosis markers, including fibrosis index based on four factors (FIB-4), aspartate to platelet ratio index (APRI) and FibroTest, on the same day were prospectively followed up for six years. Patients were classified into one of the three groups: inactive carriers (IC; HBV-DNA <2000 IU/mL and ALT <40 U/L); grey zone group 1 (GZ-1; HBV DNA <2000 IU/mL and ALT >40 U/L); grey zone group 2 (GZ-2; HBV-DNA >2000 IU/mL and ALT <40 U/L). Results: pSWE results were significantly correlated with TE (r = 0.29, p < 0.001) and APRI (r = 0.17; p = 0.005). Median pSWE values did not differ between IC, GZ-1 and GZ-2 patients (p = 0.82, p = 0.17, p = 0.34). During six years of follow-up, median pSWE and TE values did not differ significantly over time (TE: p = 0.27; pSWE: p = 0.05). Conclusion: Our data indicate that pSWE could be useful for non-invasive fibrosis assessment and follow-up in patients with HBeAg-negative chronic HBV infection.},
  language  = {en}
}